CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)

• DOI: 10.3389/fonc.2022.1061438
• Publication Date: 2022-12-01T16:27:18Z
• Authors: Yuan Jian; Zhiyao Zhang; Huixing Zhou; Guangzhong Yang; Chuanying Geng; Huijuan Wang; Wen Gao; Wenming Chen
• Keywords: Autologous stem-cell transplantation

Translocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression uncommon MM strongly associated with t(11;14). This study aimed to investigate whether could provide further patients harboring t(11;14).CD20 detected by flow cytometry was retrospectively analyzed 211 newly diagnosed The characteristics and outcomes were between positive negative patients.CD20 found 34.6% (73/211) (NDMM) t(11;14), lower serum creatine levels incidence plasmacytoma. Based on similar treatment regimens, had a comparable overall response rate patients, whereas CR/sCR (complete response/stringent complete response) than latter (31.4% vs. 46.4%, P =0.045). Nevertheless, longer tendency progression-free survival (PFS) (59.0 29.0 months, =0.163) significantly (OS) (99.0 56.0 P=0.003) patients. Further investigation among proportion showed that strong (>80% bone marrow plasma cells) exhibited longest OS (median not reached, =0.011). However, favorable impact eliminated contaminant presence besides Autologous stem cell transplantation (ASCT) improve prognosis t(11;14) Multivariate analysis confirmed an independent indicator for factor NDMM risk-stratification this heterogeneous disease subgroup.